Date:	2022-04-08
Your Na	ame: Xiaohui Lin
Manus	cript Title: Cost-effectiveness of empagliflozin as a treatment for heart failure with reduced ejection
fractior	an analysis from the Chinese healthcare perspective
Manus	cript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with	Specifications/Comments
		whom you have this	(e.g., if payments were made to you or to your
		relationship or indicate	institution)
		none (add rows as	
		needed)	
		Time frame: Since the initial	planning of the work
1	All support for the present	The project was supported	
	manuscript (e.g., funding,	by the Natural Science	
	provision of study materials,	Foundation of Fujian	
	medical writing, article	Province, China (grant No.	
	processing charges, etc.)	2020J011341) and the	
	No time limit for this item.	Health Youth Scientific	
		Research Project of Fujian	
		Province, China (grant No.	
		2021QNA075).	
		Time frame: past	36 months
2	Grants or contracts from	<u>√</u> None	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	_√_ None	

4	Consulting fees	<u> </u>	
5	Payment or honoraria for	<u> </u>	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	<u> </u>	
	testimony		
7	Support for attending	√ None	
,	meetings and/or travel		
8	Patents planned, issued or	<u>_√</u> None	
	pending		
9	Participation on a Data	None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	None	
	in other board, society,		
	committee or advocacy		
11	group, paid or unpaid Stock or stock options	√ None	
11			
12	Receipt of equipment,	√ None	
	materials, drugs, medical		
	writing, gifts or other		
	services	,	
13	Other financial or non-	None	
	financial interests		

The project was supported by the Natural Science Foundation of Fujian Province, China (grant No. 2020J011341) and the Health Youth Scientific Research Project of Fujian Province, China (grant No. 2021QNA075). The authors have no other conflicts of interest to declare.

Please place an "X" next to the following statement to indicate your agreement:

Date:	2022-04-08
Your Na	ame: Minhua Lin
Manus	cript Title: Cost-effectiveness of empagliflozin as a treatment for heart failure with reduced ejection
fractior	an analysis from the Chinese healthcare perspective
Manus	cript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with	Specifications/Comments
		whom you have this	(e.g., if payments were made to you or to your
		relationship or indicate	institution)
		none (add rows as	
		needed)	
		Time frame: Since the initial	planning of the work
1	All support for the present	The project was supported	
	manuscript (e.g., funding,	by the Natural Science	
	provision of study materials,	Foundation of Fujian	
	medical writing, article	Province, China (grant No.	
	processing charges, etc.)	2020J011341) and the	
	No time limit for this item.	Health Youth Scientific	
		Research Project of Fujian	
		Province, China (grant No.	
		2021QNA075).	
		Time frame: past	36 months
2	Grants or contracts from	<u>√</u> None	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	_√_ None	

4	Consulting fees	<u> </u>	
5	Payment or honoraria for	<u> </u>	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	<u> </u>	
	testimony		
7	Support for attending	√ None	
,	meetings and/or travel		
8	Patents planned, issued or	<u>_√</u> None	
	pending		
9	Participation on a Data	None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	None	
	in other board, society,		
	committee or advocacy		
11	group, paid or unpaid Stock or stock options	√ None	
11			
12	Receipt of equipment,	√ None	
	materials, drugs, medical		
	writing, gifts or other		
	services	,	
13	Other financial or non-	None	
	financial interests		

The project was supported by the Natural Science Foundation of Fujian Province, China (grant No. 2020J011341) and the Health Youth Scientific Research Project of Fujian Province, China (grant No. 2021QNA075). The authors have no other conflicts of interest to declare.

Please place an "X" next to the following statement to indicate your agreement:

Date: 2022	2-04-08
Your Name:	_ Maobai Liu
Manuscript	Title: Cost-effectiveness of empagliflozin as a treatment for heart failure with reduced ejection
fraction: an	analysis from the Chinese healthcare perspective
Manuscript	number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with	Specifications/Comments
		whom you have this	(e.g., if payments were made to you or to your
		relationship or indicate	institution)
		none (add rows as	
		needed)	
		Time frame: Since the initial	planning of the work
1	All support for the present	The project was supported	
	manuscript (e.g., funding,	by the Natural Science	
	provision of study materials,	Foundation of Fujian	
	medical writing, article	Province, China (grant No.	
	processing charges, etc.)	2020J011341) and the	
	No time limit for this item.	Health Youth Scientific	
		Research Project of Fujian	
		Province, China (grant No.	
		2021QNA075).	
		Time frame: past	36 months
2	Grants or contracts from	<u>√</u> None	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	_√_ None	

4	Consulting fees	<u> </u>	
5	Payment or honoraria for	<u> </u>	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	<u> </u>	
	testimony		
7	Support for attending	√ None	
'	meetings and/or travel		
8	Patents planned, issued or	<u>_√</u> None	
	pending		
9	Participation on a Data	None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	None	
	in other board, society,		
	committee or advocacy		
11	group, paid or unpaid Stock or stock options	√ None	
11			
12	Receipt of equipment,	√ None	
	materials, drugs, medical		
	writing, gifts or other		
	services	,	
13	Other financial or non-	None	
	financial interests		

The project was supported by the Natural Science Foundation of Fujian Province, China (grant No. 2020J011341) and the Health Youth Scientific Research Project of Fujian Province, China (grant No. 2021QNA075). The authors have no other conflicts of interest to declare.

Please place an "X" next to the following statement to indicate your agreement:

Date: 2022-04-08	_
Your Name: Weiying Huang	
Manuscript Title: Cost-effectiveness of empagliflozin as a treatment for heart failure with reduced ejection	
fraction: an analysis from the Chinese healthcare perspective	_
Manuscript number (if known):	_

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with	Specifications/Comments
		whom you have this	(e.g., if payments were made to you or to your
		relationship or indicate	institution)
		none (add rows as	
		needed)	
		Time frame: Since the initial	planning of the work
1	All support for the present	The project was supported	
	manuscript (e.g., funding,	by the Natural Science	
	provision of study materials,	Foundation of Fujian	
	medical writing, article	Province, China (grant No.	
	processing charges, etc.)	2020J011341) and the	
	No time limit for this item.	Health Youth Scientific	
		Research Project of Fujian	
		Province, China (grant No.	
		2021QNA075).	
		Time frame: past	36 months
2	Grants or contracts from	<u>√</u> None	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	_√_ None	

4	Consulting fees	<u> </u>	
5	Payment or honoraria for	_√_None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	<u> </u>	
	testimony		
7	Support for attending	√ None	
,	meetings and/or travel		
8	Patents planned, issued or	<u>_√</u> None	
	pending		
9	Participation on a Data	None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	None	
	in other board, society,		
	committee or advocacy		
11	group, paid or unpaid Stock or stock options	√ None	
11			
12	Receipt of equipment,	√ None	
	materials, drugs, medical		
	writing, gifts or other		
	services	,	
13	Other financial or non-	None	
	financial interests		

The project was supported by the Natural Science Foundation of Fujian Province, China (grant No. 2020J011341) and the Health Youth Scientific Research Project of Fujian Province, China (grant No. 2021QNA075). The authors have no other conflicts of interest to declare.

Please place an "X" next to the following statement to indicate your agreement:

Date:	2022-04-08	
Your Na	ame:_ Xuekun Nie	
Manus	cript Title: Cost-effectiveness of empagliflozin as a treatment for heart failure with reduced ejection	
fraction: an analysis from the Chinese healthcare perspective		
Manus	cript number (if known):	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with	Specifications/Comments
		whom you have this	(e.g., if payments were made to you or to your
		relationship or indicate	institution)
		none (add rows as	
		needed)	
		Time frame: Since the initial	planning of the work
1	All support for the present	The project was supported	
	manuscript (e.g., funding,	by the Natural Science	
	provision of study materials,	Foundation of Fujian	
	medical writing, article	Province, China (grant No.	
	processing charges, etc.)	2020J011341) and the	
	No time limit for this item.	Health Youth Scientific	
		Research Project of Fujian	
		Province, China (grant No.	
		2021QNA075).	
		Time frame: past	36 months
2	Grants or contracts from	<u>√</u> None	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	_√_ None	

4	Consulting fees	<u>√</u> None	
5	Payment or honoraria for	_√_None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
6	educational events		
6	Payment for expert	<u>√</u> None	
	testimony		
7	Current for attanding	A None	
7	Support for attending meetings and/or travel	_√_None	
8	Patents planned, issued or	_√_None	
	pending		
9	Participation on a Data	<u>_√</u> None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	_√_None	
	in other board, society,		
	committee or advocacy		
11	group, paid or unpaid	√ None	
11	Stock or stock options		
12	Receipt of equipment,	√ None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	<u>_√</u> None	
	financial interests		

The project was supported by the Natural Science Foundation of Fujian Province, China (grant No. 2020J011341) and the Health Youth Scientific Research Project of Fujian Province, China (grant No. 2021QNA075). The authors have no other conflicts of interest to declare.

Please place an "X" next to the following statement to indicate your agreement:

Date:	2022-04-08	
Your N	ame:_ Zichun Chen	
Manus	cript Title: Cost-effectiveness of empagliflozin as a treatment for heart failure with reduced ejection	
fraction: an analysis from the Chinese healthcare perspective		
Manus	cript number (if known):	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with	Specifications/Comments
		whom you have this	(e.g., if payments were made to you or to your
		relationship or indicate	institution)
		none (add rows as	
		needed)	
		Time frame: Since the initial	planning of the work
1	All support for the present	The project was supported	
	manuscript (e.g., funding,	by the Natural Science	
	provision of study materials,	Foundation of Fujian	
	medical writing, article	Province, China (grant No.	
	processing charges, etc.)	2020J011341) and the	
	No time limit for this item.	Health Youth Scientific	
		Research Project of Fujian	
		Province, China (grant No.	
		2021QNA075).	
		Time frame: past	36 months
2	Grants or contracts from	<u>√</u> None	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	_√_ None	

4	Consulting fees	<u>√</u> None	
5	Payment or honoraria for	_√_None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
6	educational events		
6	Payment for expert	<u>√</u> None	
	testimony		
7	Current for attanding	A None	
7	Support for attending meetings and/or travel	_√_None	
8	Patents planned, issued or	_√_None	
	pending		
9	Participation on a Data	<u>_√</u> None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	_√_None	
	in other board, society,		
	committee or advocacy		
11	group, paid or unpaid	√ None	
11	Stock or stock options		
12	Receipt of equipment,	√ None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	<u>_√</u> None	
	financial interests		

The project was supported by the Natural Science Foundation of Fujian Province, China (grant No. 2020J011341) and the Health Youth Scientific Research Project of Fujian Province, China (grant No. 2021QNA075). The authors have no other conflicts of interest to declare.

Please place an "X" next to the following statement to indicate your agreement:

Date: 2022-04-08	
Your Name: Bin Zheng	
Manuscript Title: <u>Cost-effectiveness of empagliflozin as a treatment for heart failure with reduced ejection</u>	
fraction: an analysis from the Chinese healthcare perspective	
Manuscript number (if known):	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with	Specifications/Comments
		whom you have this	(e.g., if payments were made to you or to your
		relationship or indicate	institution)
		none (add rows as	
		needed)	
		Time frame: Since the initial	planning of the work
1	All support for the present	The project was supported	
	manuscript (e.g., funding,	by the Natural Science	
	provision of study materials,	Foundation of Fujian	
	medical writing, article	Province, China (grant No.	
	processing charges, etc.)	2020J011341) and the	
	No time limit for this item.	Health Youth Scientific	
		Research Project of Fujian	
		Province, China (grant No.	
		2021QNA075).	
		Time frame: past	36 months
2	Grants or contracts from	<u>√</u> None	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	_√_ None	

4	Consulting fees	<u>_√</u> None	
5	Payment or honoraria for	_√_None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or educational events		
6	Payment for expert	√ None	
0	testimony		
	testimony		
7	Support for attending	√ None	
	meetings and/or travel		
8	Patents planned, issued or	None	
	pending		
9	Participation on a Data	<u> </u>	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	<u> </u>	
	in other board, society, committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	√ None	
12	Receipt of equipment,	_√_None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	<u>√</u> None	
	financial interests		

The project was supported by the Natural Science Foundation of Fujian Province, China (grant No. 2020J011341) and the Health Youth Scientific Research Project of Fujian Province, China (grant No. 2021QNA075). The authors have no other conflicts of interest to declare.

Please place an "X" next to the following statement to indicate your agreement: